Medicines Co. might conduct more trials on cangrelor

11/16/2009 | Reuters

Medicines Co. might conduct new and larger trials of intravenous blood thinner drug cangrelor in consideration of promising data on survival and blood clots. The drug failed previous trials because it did not meet main study goals, but it also showed it can significantly reduce overall mortality and blood-clot incidents related to new stents. In the event of new trials, the drug might show improved results if it is administered to patients through longer intravenous infusions, researchers said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC